Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
López-Pousa S, Garre-Olmo J, Turon-Estrada A, Hernández F, Expósito I, Lozano-Gallego M, Hernández-Ferrándiz M, Gelada-Batlle E, Pericot-Nierga I, Vilalta-Franch J
Análisis de los costes de la enfermedad de Alzheimer en función del deterioro cognitivo y funcional.
Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells.
Hong K, Brugada J, Oliva A, Berruezo-Sanchez A, Potenza D, Pollevick GD, Guerchicoff A, Matsuo K, Burashnikov E, Dumaine R, Towbin JA, Nesterenko V, Brugada P, Antzelevitch C, Brugada R
Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations.
López-Bermejo A, Fernández-Real JM, Garrido E, Rovira R, Brichs R, Genaró P, Bach C, Cabrero D, Kihara S, Funahashi T, Vendrell J, Ricart W
Maternal soluble tumour necrosis factor receptor type 2 (sTNFR2) and adiponectin are both related to blood pressure during gestation and infant's birthweight
Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R
Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
